Future research may investigate how to improve tumor infiltration, and how CAR T-cell therapy may offer synergistic effects when combined with other forms of immunotherapy such as PD-1/PD-L1 inhibitors, mRNA vaccines, T-VEC, and TIL therapy. Here, PDCD1 is linked to neoplasm.